Douglas Lane & Associates LLC Has $62,047,000 Position in Illumina Inc. (ILMN)
Douglas Lane & Associates LLC raised its position in Illumina Inc. (NASDAQ:ILMN) by 3.2% during the second quarter, Holdings Channel reports. The fund owned 441,993 shares of the life sciences company’s stock after buying an additional 13,639 shares during the period. Illumina accounts for about 1.8% of Douglas Lane & Associates LLC’s investment portfolio, making the stock its 7th largest position. Douglas Lane & Associates LLC’s holdings in Illumina were worth $62,047,000 as of its most recent filing with the SEC.
Other large investors have also added to or reduced their stakes in the company. Physicians Financial Services Inc. boosted its stake in shares of Illumina by 2,121.2% in the second quarter. Physicians Financial Services Inc. now owns 733 shares of the life sciences company’s stock worth $103,000 after buying an additional 700 shares in the last quarter. Checchi Capital Advisers LLC boosted its stake in shares of Illumina by 2.4% in the second quarter. Checchi Capital Advisers LLC now owns 958 shares of the life sciences company’s stock valued at $134,000 after buying an additional 22 shares in the last quarter. IFP Advisors Inc boosted its stake in shares of Illumina by 215.6% in the first quarter. IFP Advisors Inc now owns 1,133 shares of the life sciences company’s stock valued at $184,000 after buying an additional 774 shares in the last quarter. Simonbaker & Partners LLC bought a new stake in shares of Illumina during the first quarter valued at $243,000. Finally, First Manhattan Co. boosted its stake in shares of Illumina by 90,000.0% in the second quarter. First Manhattan Co. now owns 1,802 shares of the life sciences company’s stock valued at $252,000 after buying an additional 1,800 shares in the last quarter. Institutional investors own 95.22% of the company’s stock.
Illumina Inc. (NASDAQ:ILMN) traded up 0.10% during trading on Monday, reaching $173.15. The company’s stock had a trading volume of 487,953 shares. The firm’s 50-day moving average price is $169.55 and its 200 day moving average price is $153.59. Illumina Inc. has a 12-month low of $127.10 and a 12-month high of $198.11. The company has a market capitalization of $25.38 billion, a P/E ratio of 59.30 and a beta of 0.73.
Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, July 26th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.13. Illumina had a return on equity of 23.69% and a net margin of 18.73%. The business had revenue of $600 million for the quarter, compared to the consensus estimate of $31.91 million. During the same quarter in the previous year, the company posted $0.80 EPS. The company’s revenue was up 11.3% compared to the same quarter last year. On average, analysts predict that Illumina Inc. will post $3.53 earnings per share for the current fiscal year.
Several equities research analysts have recently weighed in on the company. Canaccord Genuity reiterated a “hold” rating on shares of Illumina in a research report on Saturday, June 4th. Cantor Fitzgerald reiterated a “hold” rating and set a $165.00 price target on shares of Illumina in a research report on Thursday, June 2nd. Zacks Investment Research upgraded Illumina from a “sell” rating to a “hold” rating in a research report on Monday, July 4th. Mizuho upped their price target on Illumina from $138.00 to $148.00 and gave the company a “neutral” rating in a research report on Wednesday, July 27th. Finally, Vetr cut Illumina from a “buy” rating to a “sell” rating and set a $142.96 price target on the stock. in a research report on Tuesday, July 26th. Two equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $163.07.
In other news, EVP Marc Stapley sold 1,270 shares of Illumina stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $172.87, for a total value of $219,544.90. Following the completion of the transaction, the executive vice president now owns 33,916 shares in the company, valued at approximately $5,863,058.92. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Jay T. Flatley sold 20,000 shares of Illumina stock in a transaction that occurred on Tuesday, August 23rd. The stock was sold at an average price of $172.99, for a total value of $3,459,800.00. Following the completion of the transaction, the director now owns 508,061 shares of the company’s stock, valued at approximately $87,889,472.39. The disclosure for this sale can be found here. 1.60% of the stock is owned by company insiders.
Illumina Company Profile
Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.